Last Price$718.2(3.6%)
Market Cap$77.0B
LTM Selling, General & Administrative Expenses (SG&A)
$2,954.4M
YoY Growth
+12.3%
3Y CAGR
+17.4%
5Y CAGR
+10.0%
Stock quality & Intrinsic value
6/10
46.0% undervalued
Regeneron Pharmaceuticals, Inc. Selling, General & Administrative Expenses (SG&A)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General & Administrative Expenses (SG&A) | $25.5M | $25.9M | $37.9M | $49.3M | $52.9M | $65.2M | $117.3M | $210.8M | $329.4M | $504.8M | $838.5M | $1,177.7M | $1,320.4M | $1,556.2M | $1,834.8M | $1,346.0M | $1,824.9M | $2,115.9M | $2,631.3M | $2,954.4M |
Overvalued or undervalued?
Check the intrinsic value for REGN
and see if it's the right time to invest.
Regeneron Pharmaceuticals, Inc. (REGN) Selling, General & Administrative Expenses (SG&A) comparison analysis
General
LTM Selling, General & Administrative Expenses (SG&A)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Regeneron Pharmaceuticals, Inc.REGN
$2,954.4M
12.3%
17.4%
10.0%
Median Peer Set
$997.4M
22.8%
19.3%
19.6%
BeiGene, Ltd.BGNE
$1,742.9M
23.0%
25.0%
40.6%
Vertex Pharmaceuticals IncorporatedVRTX
$1,464.3M
28.8%
20.3%
17.3%
Incyte CorporationINCY
$1,225.9M
5.6%
18.3%
21.2%
argenx SEARGX
$1,211.0M
90.0%
583.7%
85.1%
BioMarin Pharmaceutical Inc.BMRN
$1,019.2M
8.2%
10.3%
8.4%
Alnylam Pharmaceuticals, Inc.ALNY
$975.5M
22.6%
16.3%
15.3%
United Therapeutics CorporationUTHR
$703.7M
47.5%
14.6%
15.9%
BioNTech SEBNTX
$648.0M
4.7%
22.0%
71.1%
Royalty Pharma plcRPRX
$237.1M
(5.0%)
9.0%
18.0%
Summit Therapeutics Inc.SMMT
$60.5M
99.6%
36.8%
38.6%
REGN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 66.2 (62.0%) | 63.4 (4.1%) | 125.0 97.1% | 238.5 90.7% | 379.3 59.1% | 459.1 21.0% | 445.8 (2.9%) | 1,378.5 209.2% | 2,104.7 52.7% | 2,819.6 34.0% | 4,103.7 45.5% | 4,860.4 18.4% | 5,872.2 20.8% | 6,710.8 14.3% | 7,863.4 17.2% | 8,497.1 8.1% | 16,071.7 89.1% | 12,172.9 (24.3%) | 13,117.2 7.8% | 14,202.0 8.3% |
| Cost of Goods Sold (COGS) | 9.6 | 8.1 | 0.0 | 0.9 | 1.7 | 2.1 | 4.2 | 84.5 | 155.4 | 205.0 | 392.7 | 299.7 | 397.1 | 434.1 | 782.2 | 1,119.9 | 2,437.5 | 1,560.4 | 1,815.8 | 1,970.5 |
% margin | 56.6 85.6% | 55.3 87.2% | 125.0 100.0% | 237.5 99.6% | 377.6 99.6% | 457.0 99.5% | 441.6 99.1% | 1,294.0 93.9% | 1,949.4 92.6% | 2,614.5 92.7% | 3,711.0 90.4% | 4,560.7 93.8% | 5,475.2 93.2% | 6,276.7 93.5% | 7,081.2 90.1% | 7,377.2 86.8% | 13,634.2 84.8% | 10,612.5 87.2% | 11,301.4 86.2% | 12,231.5 86.1% |
| Operating Expenses | (67.8) | 163.0 | 239.5 | 327.4 | 451.7 | 554.5 | 646.8 | 836.3 | 1,189.4 | 1,776.1 | 2,459.1 | 3,230.0 | 3,395.6 | 3,742.3 | 4,871.4 | 3,800.6 | 4,687.4 | 5,618.5 | 7,254.3 | 8,240.8 |
| Research & Development Expenses (R&D) | 155.6 | 137.1 | 201.6 | 278.0 | 398.8 | 489.3 | 529.5 | 625.6 | 859.9 | 1,271.4 | 1,620.6 | 2,052.3 | 2,075.1 | 2,186.1 | 3,036.6 | 2,735.0 | 2,908.1 | 3,592.5 | 4,439.0 | 5,132.0 |
| Selling, General & Administrative Expenses (SG&A) | 25.5 | 25.9 | 37.9 | 49.3 | 52.9 | 65.2 | 117.3 | 210.8 | 329.4 | 504.8 | 838.5 | 1,177.7 | 1,320.4 | 1,556.2 | 1,834.8 | 1,346.0 | 1,824.9 | 2,115.9 | 2,631.3 | 2,954.4 |
% margin | 124.4 188.0% | (107.7) (169.7%) | (114.5) (91.5%) | (89.8) (37.7%) | (74.1) (19.5%) | (97.5) (21.2%) | (205.2) (46.0%) | 457.7 33.2% | 760.0 36.1% | 838.4 29.7% | 1,251.9 30.5% | 1,330.7 27.4% | 2,079.6 35.4% | 2,534.4 37.8% | 2,209.8 28.1% | 3,576.6 42.1% | 8,946.8 55.7% | 4,738.9 38.9% | 4,047.1 30.9% | 3,990.7 28.1% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 30.2 | 18.5 | 45.8 | 160.1 | 495.9 | 711.4 |
| Interest Expense | 0.0 | 0.0 | 12.0 | 7.8 | 2.3 | 9.1 | 21.3 | 45.3 | 46.4 | 37.4 | 14.2 | 7.2 | 25.1 | 28.2 | 30.2 | 56.9 | 57.3 | 59.4 | 73.0 | 55.2 |
| Pre-tax Income | 124.4 | (91.1) | (93.6) | (80.4) | (72.0) | (104.5) | (222.9) | 414.4 | 713.4 | 775.7 | 1,225.1 | 1,329.8 | 2,078.5 | 2,553.5 | 2,429.1 | 3,810.4 | 9,325.8 | 4,858.8 | 4,199.3 | 4,779.9 |
% effective tax rate | 178.8 143.7% | (21.9) 24.0% | (29.8) 31.8% | 2.4 (2.9%) | (4.1) 5.7% | (2.1) 2.0% | (1.1) 0.5% | (335.8) (81.0%) | 289.0 40.5% | 427.7 55.1% | 589.0 48.1% | 434.3 32.7% | 880.0 42.3% | 109.1 4.3% | 313.3 12.9% | 297.2 7.8% | 1,250.5 13.4% | 520.4 10.7% | 245.7 5.9% | 367.3 7.7% |
% margin | (95.4) (144.2%) | (102.3) (161.3%) | (105.6) (84.5%) | (82.7) (34.7%) | (67.8) (17.9%) | (104.5) (22.8%) | (221.8) (49.7%) | 750.3 54.4% | 424.4 20.2% | 348.1 12.3% | 636.1 15.5% | 895.5 18.4% | 1,198.5 20.4% | 2,444.4 36.4% | 2,115.8 26.9% | 3,513.2 41.3% | 8,075.3 50.2% | 4,338.4 35.6% | 3,953.6 30.1% | 4,412.6 31.1% |
| EPS | (1.71) | (1.77) | (1.59) | (1.05) | (0.85) | (1.26) | (2.45) | 7.92 | 4.23 | 3.36 | 6.17 | 8.55 | 11.27 | 21.29 | 19.38 | 32.65 | 76.40 | 40.51 | 37.05 | 40.90 |
| Diluted EPS | (1.71) | (1.77) | (1.59) | (1.05) | (0.85) | (1.26) | (2.45) | 6.75 | 3.72 | 2.98 | 5.52 | 7.70 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 |
% margin | 139.9 211.4% | (93.1) (146.7%) | (82.1) (65.6%) | (61.3) (25.7%) | (55.4) (14.6%) | (75.7) (16.5%) | (170.5) (38.3%) | 496.7 36.0% | 784.3 37.3% | 876.6 31.1% | 1,326.8 32.3% | 1,441.7 29.7% | 2,079.6 35.4% | 2,682.6 40.0% | 2,420.1 30.8% | 3,900.5 45.9% | 9,281.0 57.7% | 5,335.4 43.8% | 4,693.3 35.8% | 5,318.0 37.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Regeneron Pharmaceuticals, Inc.'s Selling, General & Administrative Expenses (SG&A)?
As of today, Regeneron Pharmaceuticals, Inc.'s last 12-month Selling, General & Administrative Expenses (SG&A) is $2,954.4M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Regeneron Pharmaceuticals, Inc.'s Selling, General & Administrative Expenses (SG&A) growth rate?
Over the last year, Regeneron Pharmaceuticals, Inc.'s Selling, General & Administrative Expenses (SG&A) growth was 12.3%. The average annual Selling, General & Administrative Expenses (SG&A) growth rates for Regeneron Pharmaceuticals, Inc. have been 26.8% over the past three years, 10.0% over the past five years.
3) Is Regeneron Pharmaceuticals, Inc.'s Selling, General & Administrative Expenses (SG&A) growth rate Good?
Over the last year, Regeneron Pharmaceuticals, Inc.'s Selling, General & Administrative Expenses (SG&A) growth was 12.3%, which is higher than industry growth of 0.0%. It indicates that Regeneron Pharmaceuticals, Inc.'s Selling, General & Administrative Expenses (SG&A) growth is Bad.